News

What are the cultural, religious, philosophical, and psychological factors that differentiate Eastern and Western values regarding assisted suicide and euthanasia?

New analysis links traumatic brain injury to later psychosis, prompting long-term screening and follow-up.

Often the best opportunities for mental health growth come when psychiatry, religions, and spirituality can enhance one another.

A novel form of agomelatine shows positive initial results.

Phase 2 trial of oveporexton for narcolepsy type 1 finds improvement on measures of cognition, in addition to previously demonstrated improved hallmark symptom of nighttime wakefulness.

Lipocine's oral brexanolone (LPCN 1154) for the treatment of postpartum depression failed to meet the primary endpoint in a phase 3 placebo-controlled trial.

Pop psychiatry fuels misdiagnosis of autism or ADHD, delaying psychosis and bipolar treatment—why accurate labels and early meds save lives.

Yesterday, we launched a spaceship the moon for the first time in 53 years. What implications does this journey have for psychiatry?

An interview with Felice Jacka, OAM, PhD, on the rapidly developing field of nutritional psychiatry.

New initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo in adults with narcolepsy type 1 and type 2.

Explore fresh clinical insights on schizophrenia—mortality, stigma, cannabis links, lifestyle, and new treatments—and share cases for our April series.

Q1 psychiatric pipeline shifts: wins, setbacks, and standout trials in depression, schizophrenia, Alzheimer disease, and narcolepsy—what to watch next.

How will AI influence psychiatry training?

Being a fool can run from being thought to be inappropriately silly to Shakespeare’s fools of creative wisdom. Where does psychiatry come in?

Elite coaches often run on severe sleep loss, risking impaired decisions, emotion control, and leadership.

Continuity vs discontinuity, tradition vs change in the “psy disciplines.”

Check out the pipeline updates from March!

Further data shared on LB-102 for schizophrenia.

A panel of experts presented new consensus recommendations focused on the screening, diagnosis, and treatment of tardive dyskinesia among older adults in long-term care settings.

Tazbentetol interim results show improvement in schizophrenia symptoms.

ASAM announces new youth substance use disorder criteria, promoting early intervention, family-focused care, integrated mental health, and updated levels of treatment.

Why men struggle in silence: suicide risks, hidden depression signs, and practical ways therapy and connection help.

How medical conferences cut carbon footprint: greener travel, water stations, compostables, recycled badges, and offsets—AAP’s 2025 model.

LB Pharmaceuticals has initiated the pivotal phase 3 NOVA-2 trial evaluating the efficacy and safety of LB-102 as a treatment for schizophrenia.

Learn more about why shared decision-making fails across cultures—and how a quick wind-check helps clinicians adapt recovery care without losing trust.

Resort thrillers glamorize hotel killings, but data reveals a quieter risk: planned suicides by local guests—and warning signs clinicians can spot.

New lawsuits target social media and chatbots that could reshape AI regulation and protect youth mental health.

Near 80, a psychiatrist rediscovers joy in family, music, and purpose—while facing mortality and the bittersweet truths of aging.

AD/PD 2026 highlights oral blarcamesine preserving brain volume and IV lecanemab sustaining use while clearing amyloid-beta.

Learn how clinicians distinguish grief from depression, when sadness turns impairing, and which therapies and meds help people heal after loss.